Given the potential for cardiac dysfunction with trastuzumab—and, in particular, with anthracycline-containing chemotherapy—the TRYPHAENA study was designed to assess the safety and tolerability of neoadjuvant HP + anthracycline-containing chemotherapy vs. HP + anthracycline-free chemotherapy in 225 patients with HER2+ operable, locally advanced, or inflammatory breast cancer with primary tumours > 2 cm in diameter [36]. The gene discussed is ERBB2; the disease is neoplasm.